Skip to main content
OpenTrials
Completed

NCT Number: NCT05560841

Effectiveness and Safety of Nailner Brush 2in1 in Onychomycosis

Evaluate the effectiveness of Nailner Brush 2-in-1 in the treatment of onychomycosis based on the blinded evaluation of the percentage of healthy nail surface after 6 months of treatment compared to baseline.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Private practice, Ben Arous, Tunisia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient having given freely her/his informed, written consent.
  • Patient having a good general health.
  • Age: between 18 and 70 years.
  • Patient with superficial onychomycosis or light to moderate distolateral onychomycosis (without matrix involvement and involvement from 10 to 60%) on at least one great toenail.
  • Patient with positive KOH staining.
  • Patient cooperative and aware of the device modalities of use and the necessity and duration of the controls so that perfect adhesion to the protocol can be expected.
  • Patient being psychologically able to understand information and to give their/his/her consent.
  • Patient who agrees to refrain from receiving pedicure, artificial nails and/or cosmetic nail varnish or other medication on the nail being treated for the entire study duration.
  • Female of childbearing potential should use a contraceptive regimen recognized as effective since at least 4 weeks before screening visit and during all the study.

Exclusion criteria

  • Pregnant, breastfeeding woman or woman planning a pregnancy during the study;
  • Patient enrolled in another clinical trial or which exclusion period is not over.
  • Patient having used any systemic antifungal treatment in the last 6 months before screening and/or any topical antifungal treatment in the last months before screening visit.
  • Patient with a condition or receiving a medication which, in the investigator's judgment, put the patient at undue risk;
  • Patient suffering from a severe or progressive disease (at investigator's discretion) such as uncontrolled diabetes, peripheral circulatory disease, poor blood circulation HIV, psoriasis, lichen planus, immunosuppressive pathology, moderate and high risk obesity (BMI ≥30);
  • Patient having a known allergy or hypersensitivity to one of the constituents of the investigational device.
  • Patient with cutaneous pathology on studied zone (other than onychomycosis like angioma, dermatitis…).

Treatment and study plan

topical treatment

Device

Topical application of Nailner brush 2in1 for toenail onychomycosis

Primary outcomes

  1. To evaluate the effectiveness of Nailner Brush 2-in-1 in the treatment of onychomycosis based on the blinded evaluation of the percentage of healthy nail surface after 6 months of treatment compared to baseline

    Time frame: Day 180

    Mean variation from baseline of the percentage of healthy surface after 6 months of treatment. Evaluation is done in blind by digital analysis of photographs of the infected toenail.

Secondary outcomes

  1. To evaluate the effectiveness of Nailner Brush 2-in-1 in the treatment of onychomycosis based on the blinded evaluation of the percentage of healthy nail surface after 1 and 3 months of treatment compared to baseline

    Time frame: Day 30, Day 90

    Mean variation from baseline of the percentage of healthy surface after 1 and 3 months of treatment. Evaluation is done in blind by digital analysis of photographs of the infected toenail.

  2. To evaluate the effectiveness of Nailner Brush 2-in-1 in the treatment of onychomycosis based on the microbiological cure (KOH staining)

    Time frame: Day 90, Day 180

    Percentage of patients with positive KOH staining at baseline and 3 and 6 months after treatment.

  3. To evaluate the effectiveness of Nailner Brush 2-in-1 in the nail appearance

    Time frame: Day 30, Day 90, Day180

    Mean variation from baseline of the onychomycosis evaluation ( onycholysis, nail dystrophy, nail discoloration and nail thickening) as assessed by the investigator in live at baseline and 1, 3 and 6 months after treatment.

  4. To evaluate the effectiveness of Nailner Brush 2-in-1 in the improvement of the quality of life (QoL) of the patients.

    Time frame: Day 7, Day 30, Day 90, Day 180

    Percentage of patient with an improvement of their quality of life (QoL) by analysis of NailQoL p

  5. To evaluate the patient's opinion of Nailner Brush 2-in-1 effectiveness, tolerance, and acceptability.

    Time frame: Day 30, Day 90, Day 180

    Analysis of the answers to the patient questionnaire regarding effectiveness, tolerance, and acceptability of the investigational device 1, 3 and 6 months after treatment

  6. To evaluate the safety of of Nailner Brush 2-in-1

    Time frame: Day 180

    Product safety will be assessed by collection of Adverse Events (Aes) throughout the study. AEs will be summarized and tabulated by severity, causality, action taken and outcome, using descriptive statistics

Sponsors and collaborators

Lead sponsor

Karo Pharma AB

Industry

Registry information

Official study title

Prospective, " Evaluator Blinded " Clinical Investigation to Evaluate the Effectiveness and Safety of Nailner Brush 2-in-1 in the Treatment of Onychomycosis

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Sep 29, 2022
Registry last updated
Oct 4, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.